California judge rules Allergan, Endo, Johnson & Johnson, and Teva not liable for state's opioid crisis; CDC panel to decide on approval of and recommendations for Pfizer/BioNTech's COVID-19 vaccine in children aged 5 to 11 years; screen time among teenagers more than doubled during the pandemic.
Yesterday, Superior Court Judge Peter J. Wilson of California rejected claims that 4 drug companies—Allergan, Endo, Johnson & Johnson, and Teva—used false and misleading marketing to promote the sale of prescription opioids. Reported by NPR, the ruling indicates that the 4 drug companies cannot be held liable for California’s opioid crisis. If found guilty, they would have had to pay for several costly public health and drug treatment programs. There are several other opioid lawsuits in state and federal courts nationwide, with cases currently underway in New York, Ohio, and West Virginia.
A special advisory panel from the CDC is meeting today to consider recommendations for administering Pfizer/BioNTech’s COVID-19 vaccine in children aged 5 to 11 years, with The Associated Press reporting that the Biden administration, anticipating approval from advisors, is beginning to assemble and ship millions of shots. Delivering a dose that is one-third of the vaccine given to adults, White House Coronavirus Response Coordinator Jeff Zients said the government has enough vaccine for all 28 million young children of the age group. Pending approval, the first shots could be given to children by midweek. Parents will be able to go to vaccines.gov and filter on vaccines for children 5 to 11 to find a location near them that is offering the vaccine.
As reported by USA Today, a study published yesterday in JAMA Pediatrics found that screen time among teenagers outside of virtual school more than doubled from 3.8 hours per day before the pandemic to 7.7 hours per day in 2020. Leveraging data from the Adolescent Brain Cognitive Development Study, the data also show that children of color and those of lower-income families reported greater screen time than their White, wealthier counterparts. Because participants were asked to self-report screen use, wellness experts noted that study projections may be underreported and that estimates are likely greater in teens.
No Major Shifts in OBGYN Practice Locations Found Post Dobbs Decision
April 21st 2025Despite widespread concern following the Dobbs v Jackson Women’s Health Organization decision, researchers found no significant changes nationwide in obstetrician and gynecologist (OBGYN) practice locations.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health
April 18th 2025Health care disparities are often driven by where patients live, explained Antoine Keller, MD, as he discussed the complex, systematic hurdles that influence the health of rural communities.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More